X

Trial Profile

First of two planned phase II trials of betalutin for the treatment of non-Hodgkin's lymphoma

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 29 Sep 2016

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium-177 lilotomab satetraxetan (Primary)
Indications Non-Hodgkin's lymphoma
Focus Registrational; Therapeutic Use
Acronyms PARADIGME

Most Recent Events

24 Aug 2016 According to a Nordic Nanovector media release, optimized dose regimen of Lymrit 37-01 study will be used in PARADIGME study which is planned to start in 2H 2017.
18 Aug 2016 Planned initiation date changed from 1 Jan 2017 to 1 Jul 2017 according to a Nordic Nanovector media release.
15 Apr 2016 According to a Nordic Nanovector media release, the pivotal PARADIGME study expected to start in Q1 2017.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com